AbbVie: Balance Is Everything
by Gary Gambino
Contributor since 2019 / 4863 Followers
Contributor since 2019 / 4863 Followers
2 years ago
Summary: AbbVie’s future growth depends on improving its balance of drugs offered, in contrast to
ABBV
AbbVie: Still A Buy According To Buffett’s 10xEBT Rule
by Sensor Unlimited
Contributor since 2021 / 6959 Followers
Contributor since 2021 / 6959 Followers
2 years ago
Summary: AbbVie investors have good reason to be concerned about the company’s future return potential.
Abbott Labs Vs AbbVie: Which One Is The Best Investment Choice?
by Bill Zettler
Contributor since 2015 / 13962 Followers
Contributor since 2015 / 13962 Followers
2 years ago
Summary: Abbott Labs spun off AbbVie in 2013. AbbVie has lost patent protection on its
Unveiling AbbVie’s Hidden Risks: Cautionary Notes For Investors
by Nathan Aisenstadt
Contributor since 2021 / 3975 Followers
Contributor since 2021 / 3975 Followers
2 years ago
Summary: AbbVie’s Q2 2023 financial results exceeded expectations, driven by strong sales of innovative drugs
AbbVie Q2 2023 Earnings Preview: Pharma Faces Toughest Test, Street Demands Answers
by Edmund Ingham
Contributor since 2018 / 9510 Followers
Contributor since 2018 / 9510 Followers
2 years ago
Summary: AbbVie Inc. will announce its Q2 2023 earnings this Thursday, July 27, ahead of
AbbVie: Loss Of Exclusivity Is A Natural End Process
by Juxtaposed Ideas
Contributor since 2022 / 7335 Followers
Contributor since 2022 / 7335 Followers
2 years ago
Summary: AbbVie has had some big shoes to fill indeed, due to the loss of
AbbVie: Dancing On Humira’s Grave
by Vera Glebova
Contributor since 2022 / 1051 Followers
Contributor since 2022 / 1051 Followers
2 years ago
Summary: AbbVie’s flagship drug Humira is facing competition from biosimilars, but the company is expected
More Challenges Await AbbVie Following A Disappointing Quarter
by Nathan Aisenstadt
Contributor since 2021 / 3813 Followers
Contributor since 2021 / 3813 Followers
2 years ago
Summary: On July 27, 2023, AbbVie Inc., one of the leaders in the global immunology
AbbVie: Humira Overhang Is A Fantastic Buying Opportunity
by JR Research
Contributor since 2021 / 25748 Followers
Contributor since 2021 / 25748 Followers
2 years ago
Summary: AbbVie Inc. has lowered its adjusted EPS guidance range for Q2 and FY23 due
AbbVie: A Buy Despite Declining Humira Sales
by Daniel Schönberger
Contributor since 2016 / 10987 Followers
Contributor since 2016 / 10987 Followers
2 years ago
Summary: AbbVie underperformed the S&P 500 in the last few months – similar to the